• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Zool Res . Cross-species recognition of bat coronavirus RsYN04 and cross-reaction of SARS-CoV-2 antibodies against the virus

tetano

Editor, Senior Moderator
Zool Res


. 2023 Nov 18;44(6):1015-1025.
doi: 10.24272/j.issn.2095-8137.2023.187. Cross-species recognition of bat coronavirus RsYN04 and cross-reaction of SARS-CoV-2 antibodies against the virus

Runchu Zhao[SUP] 1 2 [/SUP], Sheng Niu[SUP] 3 [/SUP], Pu Han[SUP] 2 [/SUP], Yue Gao[SUP] 2 4 [/SUP], Dezhi Liu[SUP] 1 2 [/SUP], Chunliang Luo[SUP] 2 3 [/SUP], Honghui Liu[SUP] 2 [/SUP], Bo Liu[SUP] 2 3 [/SUP], Yanli Xu[SUP] 5 [/SUP], Jianxun Qi[SUP] 2 [/SUP], Zhihai Chen[SUP] 5 [/SUP], Weifeng Shi[SUP] 6 [/SUP], Lili Wu[SUP] 7 [/SUP], George F Gao[SUP] 2 8 [/SUP], Qihui Wang[SUP] 1 2 9 [/SUP]



Affiliations
Free article Abstract

in English, Chinese
Following the outbreak of coronavirus disease 2019 (COVID-19), several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronaviruses have been discovered. Previous research has identified a novel lineage of SARS-CoV-2-related CoVs in bats, including RsYN04, which recognizes human angiotensin-converting enzyme 2 (ACE2) and thus poses a potential threat to humans. Here, we screened the binding of the RsYN04 receptor-binding domain (RBD) to ACE2 orthologs from 52 animal species and found that the virus showed a narrower ACE2-binding spectrum than SARS-CoV-2. However, the presence of the T484W mutation in the RsYN04 RBD broadened its range. We also evaluated 44 SARS-CoV-2 antibodies targeting seven epitope communities in the SARS-CoV-2 RBD, together with serum obtained from COVID-19 convalescents and vaccinees, to determine their cross-reaction against RsYN04. Results showed that no antibodies, except for the RBD-6 and RBD-7 classes, bound to the RsYN04 RBD, indicating substantial immune differences from SARS-CoV-2. Furthermore, the structure of the RsYN04 RBD in complex with cross-reactive antibody S43 in RBD-7 revealed a potently broad epitope for the development of therapeutics and vaccines. Our findings suggest RsYN04 and other viruses belonging to the same clade have the potential to infect several species, including humans, highlighting the necessity for viral surveillance and development of broad anti-coronavirus countermeasures.

Keywords: ACE2; Antibody; RsYN04; SARS-CoV-2-related coronavirus; Structure.

 
Back
Top Bottom